Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1.
BCL2A1
BFL-1
NFκB signaling pathway
pro-survival BCL-2
relapsed/refractory multiple myeloma
signal transduction pathway activity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Sep 2021
17 Sep 2021
Historique:
received:
23
07
2021
revised:
13
09
2021
accepted:
15
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Multiple myeloma (MM) is a hematological malignancy that is still considered incurable due to the development of therapy resistance and subsequent relapse of disease. MM plasma cells (PC) use NFκB signaling to stimulate cell growth and disease progression, and for protection against therapy-induced apoptosis. Amongst its diverse array of target genes, NFκB regulates the expression of pro-survival BCL-2 proteins BCL-XL, BFL-1, and BCL-2. A possible role for BFL-1 in MM is controversial, since BFL-1, encoded by
Identifiants
pubmed: 34572895
pii: cancers13184668
doi: 10.3390/cancers13184668
pmc: PMC8467450
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : KWF Kankerbestrijding
ID : UU 2015-7663
Organisme : KWF Kankerbestrijding
ID : 11108
Références
Blood. 2009 Jul 30;114(5):1046-52
pubmed: 19436050
Cancer Cell. 2007 Aug;12(2):131-44
pubmed: 17692805
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Br J Haematol. 2004 May;125(3):373-82
pubmed: 15086420
Semin Immunol. 2006 Oct;18(5):263-75
pubmed: 16914324
Cell Chem Biol. 2020 Jun 18;27(6):647-656.e6
pubmed: 32413285
Cancer Cell. 2013 Jan 14;23(1):48-62
pubmed: 23328480
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32961868
EMBO J. 1994 Nov 15;13(22):5433-41
pubmed: 7957109
Hematol Oncol. 2019 Jun;37 Suppl 1:62-65
pubmed: 31187526
Blood. 2016 Sep 29;128(13):1735-44
pubmed: 27516441
Cancer Cell. 2007 Aug;12(2):115-30
pubmed: 17692804
Blood. 2015 May 14;125(20):3069-75
pubmed: 25838344
Cancer Res. 2014 Jun 1;74(11):2936-45
pubmed: 24695361
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Blood. 2010 Oct 7;116(14):2543-53
pubmed: 20574050
Semin Cancer Biol. 2016 Aug;39:68-76
pubmed: 27544796
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918370
Am J Hematol. 2021 Apr 1;96(4):418-427
pubmed: 33368455
Blood. 2007 Feb 15;109(4):1692-700
pubmed: 17023574
Front Oncol. 2018 Nov 20;8:533
pubmed: 30524962
Sci Rep. 2019 Feb 7;9(1):1603
pubmed: 30733525
Oncotarget. 2010 May;1(1):59-68
pubmed: 20890394
Oncogene. 2002 Aug 22;21(37):5673-83
pubmed: 12173037
Leukemia. 2016 Mar;30(3):761-4
pubmed: 26174630
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
J Biol Chem. 2001 Jun 22;276(25):22382-7
pubmed: 11297551
Cancers (Basel). 2020 Aug 06;12(8):
pubmed: 32781681
Curr Opin Hematol. 2008 Jul;15(4):391-9
pubmed: 18536579
Blood. 2004 Apr 15;103(8):3148-57
pubmed: 15070697
Nat Commun. 2014;5:2997
pubmed: 24429703
Blood Rev. 2019 Mar;34:56-66
pubmed: 30501907
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Blood. 2005 Jul 1;106(1):296-303
pubmed: 15755896
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
Oncotarget. 2016 Mar 1;7(9):9666-79
pubmed: 26575327
Immunity. 2002 Jul;17(1):51-62
pubmed: 12150891
Cell Death Differ. 2012 Jan;19(1):67-74
pubmed: 22075983
Blood. 2002 Jun 1;99(11):4079-86
pubmed: 12010810